官方服务：
资源简介：
Benign tumors vs. cancer, AUC > 0.7.
应用场景：
创建时间：
2020-10-19
相关数据集
Diagnostic performances of CEA, CA15-3 and CYFRA 21-1 at cutoff levels, US-FNAB alone, and US-FNAB combined with each tumor marker.
–Raw data in parentheses, †values compared to US-FNAB, *values compared to US-FNAB combined with CYFRA 21-1.
NIAID Data Ecosystem40
Tumor Markers Immunoassay Market
Global Tumor Markers Immunoassay Market Report 2021 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market
IMR REPORTS20
Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on treatment type and tumor response.
Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on treatment type and tumor response.
Figshare2016-06-21 更新10
Differential immunoreactivity of prominin-1 and other cancer markers in distinct salivary gland diseases.
CEA, carcinoembryonic antigen; MUC1, mucin 1.*Occurrence: p, peripheral; h, hemorrhagic; i, inflammatory tumor areas.#Occurrence of 80B258- and AC133-positive non-tumoral ductal structures between can
Figshare2015-12-02 更新30
Table_3_MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer.xlsx
Papillary thyroid cancer (PTC) is one of the malignancies with an excellent prognosis. However, in PTC, progression or dedifferentiation into poorly differentiated thyroid cancer (PDTC) or anaplastic
NIAID Data Ecosystem10
